The 23

Atmo Biosciences

Demystifying the human gut microbiome

RapidAim logo


Dr Kyle Berean VP Technology

Dr Adam Chrimes Principal Engineer

Malcolm Hebblewhite CEO

Dr James John VP Operations

Get in Contact
T: 0418 465 728

Atmo Biosciences is a digital health business developing the world’s first ingestible, gas-sensing capsule for monitoring the health of the human gut and its microbiome.
Atmo’s gas-sensing capsule continuously measures clinically important gaseous biomarkers as it travels through the gut and transmits the data wirelessly to the cloud for aggregation and analysis, providing gastroenterologists and researchers with objective insights into microbiome function and gut health. This enables improved diagnosis and more personalised treatment for common gastrointestinal disorders — leading to earlier relief of symptoms and improved healthcare outcomes for the millions of sufferers worldwide.

What does success look like to you?

Commercialising a medical device that improves quality of life for the millions of sufferers of common GI conditions, and demystifying microbiome function by opening up a window and shining a light on what is the black box of gut physiology.


Malcolm Hebblewhite

Co-founder and CEO, Atmo Biosciences

Malcolm Hebblewhite is an executive and entrepreneur with more than 25 years of technical, commercial and international business experience in medical device and technology-based product development. Mal was a pre-IPO employee of ResMed (NYSE:RMD;ASX:RMD), and held executive roles of increasing responsibility for the company in business development, marketing and M&A in Australia, the USA, and Europe. More recently, Mal worked in commercial and business development roles at leading healthtech innovation company Planet Innovation, before founding Atmo Biosciences in 2018. He holds a B.E.(Hons)(Aerospace) from UNSW, an MBA from the Kellogg Graduate School of Business at Northwestern University.
tech 23 dots

Would you like to call out a mentor who has helped your company? Tell us a little about them.

Professor Peter Gibson, chief clinical advisor, who has provided dedicated and valuable leadership throughout the life of the company. Professor Kourosh Kalantar-zadeh, leader of the group at RMIT that invented the technology, for his vision and creativity.

Check out the rest of The 23…